Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 186-190

  Mitsuhashi, Hiroshi ^a   Tamura, Kouichi ^a   Yamauchi, Junji ^a   Ozawa, Motoko ^a   Yanagi, Mai ^a   Dejima, Toru ^a   Wakui, Hiromichi ^a   Masuda, Shin ichiro ^a   Azuma, Koichi ^a   Kanaoka, Tomohiko ^a   Ohsawa, Masato ^a   Maeda, Akinobu ^a   Tsurumi Ikeya, Yuko ^a   Okano, Yasuko ^a   Ishigami, Tomoaki ^a   Toya, Yoshiyuki ^a   Tokita, Yasuo ^b   Ohnishi, Toshimasa ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Fujisawa Municipal Hospital   (Japan)

Author keywords

Advanced glycation end product; Ambulatory blood pressure; Angiotensin II type 1 receptor blocker; Blood pressure variability; Hemodialysis; Left ventricular hypertrophy; Natriuretic peptide; Pulse wave velocity

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOSARTAN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADIPONECTIN; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANKLE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BRACHIAL ARTERY; CIRCADIAN RHYTHM; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPOPROTEINS, LDL; LOSARTAN; MALE; MALONDIALDEHYDE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; REGRESSION ANALYSIS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 70350232956     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.005     Document Type: Article

References (20)

1. Foley R., Parfrey P., Harnett J., et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49 (1996) 1379-1385
2. Harnett J., Kent G., Barre P., Taylor R., and Parfrey P. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 4 (1994) 1486-1490
3. Parfrey P., Foley R., Harnett J., et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11 (1996) 1277-1285
4. Mancia G., and Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 36 (2000) 894-900
5. Parati G., Di Rienzo M., and Mancia G. Neural cardiovascular regulation and 24-hour blood pressure and heart rate variability. Ann NY Acad Sci 783 (1996) 47-63
6. Shintani Y., Kikuya M., Hara A., et al. Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: the Ohasama study. J Hypertens 25 (2007) 1704-1710
7. Kikuya M., Hozawa A., Ohokubo T., et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 36 (2000) 901-906
8. Sander D., Kukla C., Klingelhofer J., Winbeck K., and Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 102 (2000) 1536-1541
9. Eto M., Toba K., Akishita M., et al. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 28 (2005) 1-7
10. Tamura K., Tsurumi Y., Sakai M., et al. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 29 (2007) 31-42
11. Yamashina A., Tomiyama H., Takeda K., et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25 (2002) 359-364
12. Shibasaki Y., Masaki H., Nishiue T., et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 90 (2002) 256-261
13. Nishikimi T., Futoo Y., Tamano K., et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 37 (2001) 1201-1208
14. Mallamaci F., Zoccali C., Tripepi G., et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59 (2001) 1559-1566
15. Zoccali C., Mallamaci F., Benedetto F.A., et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12 (2001) 1508-1515
16. Matayoshi T., Kato T., Nakahama H., et al. Brain natriuretic peptide in hemodialysis patients: predictive value for hemodynamic change during hemodialysis and cardiac function. Am J Nephrol 28 (2008) 122-127
17. Kalousova M., Zima T., Tesar V., Sulkova S., and Fialova L. Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney Int Suppl (2003) S62-S64
18. Hou F.F., Ren H., Owen Jr. W.F., et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15 (2004) 1889-1896
19. Candido R., Forbes J.M., Thomas M.C., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92 (2003) 785-792
20. Coskun C., Kural A., Doventas Y., et al. Hemodialysis and protein oxidation products. Ann NY Acad Sci 1100 (2007) 404-408